UPDATE : Thursday, November 14, 2019
Regulator, Kolon rebuked for slow response to Invossa problem
Late February: Kolon Life Science, Kolon TissueGene recognize mislabeled ce...
by Jeong Sae-im  |  2019-04-11 14:46
Canada OKs Celltrion’s Truxima
Celltrion said Thursday that it has received regulatory approval for Truxim...
by Lee Han-soo  |  2019-04-11 11:33
Patients may file class-action lawsuit against Kolon for mislabeling Invossa
Korean patients, who received Invossa-K injection for degenerative arthriti...
by Jeong Sae-im  |  2019-04-10 14:41
Celltrion, iProgen to co-develop novel antibody-drug conjugates
Celltrion has signed a development partnership agreement with iProgen Biote...
by Lee Han-soo  |  2019-04-09 16:04
Kolon’s foreign partners await cell analysis results
The overseas business partners of Kolon Life Science are waiting for the re...
by Jeong Sae-im  |  2019-04-08 14:28
Kolon Life Science criticized for poor quality control on Invossa
Researchers are raising suspicions over the Kolon Life Science’s clarificat...
by Jeong Sae-im  |  2019-04-05 12:27
‘Invossa, first treatment to have used cancerous cell lines’
Biotech experts raised a safety concern for Invossa-K, a degenerative arthr...
by Jeong Sae-im  |  2019-04-04 15:24
Celltrion completes patient registration for Humira biosimilar
Celltrion said Thursday that it has completed registering patients for its ...
by Lee Han-soo  |  2019-03-28 18:04
Alteogen wins patent on SC injection formulation for Herceptin biosimilar
Alteogen said Wednesday that it has patented a formulation for ALT-LS2, a s...
by Lee Han-soo  |  2019-03-28 15:04
GC’s US branch opens new plasma collection centers
GCAM (Green Cross America), GC’s U.S. offshoot, said Tuesday that it has op...
by Lee Han-soo  |  2019-03-27 10:43
Celltrion licenses out hypertrophic cardiomyopathy treatment to Japan
Celltrion said Monday that it has signed an exclusive sales agreement with ...
by Lee Han-soo  |  2019-03-25 15:41
Regulator OKs Medipost’s P1 trial of knee osteoarthritis treatment
Medipost said Thursday that the Ministry of Food and Drug Safety has approv...
by Lee Han-soo  |  2019-03-22 14:22
Samsung Bioepis unveils 3-year follow-up data for Ontruzant
Samsung Bioepis said Friday that it has presented the three-year follow-up ...
by Lee Han-soo  |  2019-03-22 14:05
'US sales of Truxima imminent'
Celltrion Chairman Seo Jung-jin said Wednesday that U.S. sales for Truxima,...
by Jeong Sae-im  |  2019-03-20 17:59
Samsung BioLogics, Eutilex to develop anti-cancer immunotherapies
Samsung BioLogics said Wednesday that it has signed a contract development ...
by Lee Han-soo  |  2019-03-20 17:18
Samsung Bioepis nullifies patents related to Herceptin in Korea
Samsung BioEpis has succeeded in nullifying the patent for cancer treatment...
by Lee Han-soo  |  2019-03-18 15:51
Thea, OliX to cooperate in developing age-related macular degeneration treatment
OliX Pharmaceuticals said Monday it has signed a license and collaboration ...
by Lee Han-soo  |  2019-03-18 12:02
CHA Biotech revises separate operating profit to a loss in 2018
CHA Biotech announced Thursday that the company revised its separate operat...
by Jeong Sae-im  |  2019-03-15 16:26
'OliX to target global market with RNA technology'
OliX Pharmaceutical’s RNAi (RNA interference) technology is getting the not...
by Lee Han-soo  |  2019-03-15 11:44
Loss-making Medipost seeks to avoid administrative issue designation
Medipost, a company specializing in stem cell research, is drawing the indu...
by Jeong Sae-im  |  2019-03-14 14:33
Back to Top